ONCE Spark Therapeutics Inc.

-0.09  -0%
Previous Close 110.71
Open 110.7
Price To Book 8.46
Market Cap 4200385427
Shares 37,971,302
Volume 1,237,597
Short Ratio
Av. Daily Volume 2,363,298

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated late 2018. Phase 1/2 further data due mid-2019.
Hemophilia A
Phase 1/2 updated data released May 22, 2018 - 98% decrease in bleeding rate.
Hemophilia B
Phase 1/2 ongoing.
SPK-7001 (SPK-CHM)
PDUFA date January 12, 2018 under priority review. Advisory Committee Meeting October 12, 2017 voted 16-0 in favor of recommending approval. Approval announced December 19, 2017.
Luxturna (voretigene neparvovec)
Inherited retinal dystrophies
Phase 3 lead-in trial initiation announced July 16, 2018.
FIX Replacement therapy
Hemophilia B

Latest News

  1. Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs
  2. Spark Therapeutics Announces Sponsorship of Believe Limited’s First-Ever Science Fair for the Hemophilia Community at 2019 National Hemophilia Foundation’s Bleeding Disorders Conference
  3. Swiss drugmaker Roche ups outlook as sales growth offsets price hit
  4. Spark Therapeutics (ONCE) Merger Class Action Lawsuit: Halper Sadeh LLP Announces Filing of Shareholder Class Action Lawsuit Against Spark Therapeutics, Inc. Concerning Its Proposed Merger With Roche Holdings, Inc. – ONCE
  5. Ophthotech Gets Rights to Gene Therapy for BEST Disease
  6. Biotechnology Market on a Tear: 5 ETFs in Spotlight
  7. COMPLAINTS FILED - ELLI and ONCE: Levi & Korsinsky, LLP Reminds Investors of Complaints Filed Concerning the Sale of these Companies
  8. 4 Gene Therapy Players Likely to Become Buyout Targets in 2019
  9. Health Day Checkup of Medical ETFs: 5 Top Picks
  10. Rigrodsky & Long, P.A. Files Class Action Suit Against Spark Therapeutics, Inc.
  11. Deals of the day-Mergers and acquisitions
  12. Roche extends deadline for Spark Therapeutics shareholders in $4.8B deal
  13. Sangamo Rises on Positive Phase I/II Hemophilia Study Data
  14. Roche Extends Offer Period for Spark Therapeutics Acquisition
  15. Roche Buys More Time in $4.3B Offer for Spark Therapeutics
  16. The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings
  17. Roche says $4.3 billion Spark offer still on track for June completion
  18. European shares climb for fourth day on trade optimism, China data
  19. Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.